Amarin Corp Plc (AMRN)

[jfmcrr]

Dr. Corral is just refering to the following publication:

https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehab643/6380417

Current European guidelines recommend consideration of icosapent ethyl in combination with statin therapy for high- and very-high-risk patients with triglyceride concentrations in the range of 135–499 mg/dL (1.5–5.6 mmol/L) despite statin treatment for reduction of ASCVD risk.17 The analysis by Doi et al. provides support for this recommendation, although important questions remain.7 Additional randomized, controlled trials of ASCVD outcomes and surrogate indicators, such as coronary plaque progression, will be needed to further clarify the magnitude of the effect of icosapent ethyl on ASCVD incidence, and the mechanisms responsible for such benefits.

The benefits of icosapent ethyl stand. The paper explores the mechanism and says there is more to be done.

Way too much emotion and hysteria prevents reading comprehension.